Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal.
We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment. Demographic and clinical data were collected.
Median visual acuity (VA) and central macular thickness (CMT) improved in the branch RVO (BRVO), central RVO (CRVO), bevacizumab, and ranibizumab groups at 6 and 12 months compared to baseline, with CMT improving further only in the CRVO and ranibizumab groups between 6 and 12 months (p = 0.002 and p = 0.001, respectively). The CMT was lower in the ranibizumab group compared to the bevacizumab group both at 6 and 12 months (p<0.02). Median CMT improved in both the good and poor baseline VA groups at 6 and 12 months compared to baseline (p<0.001). Median VA only improved for the group with poor baseline VA at 6 and 12 months of follow-up (p<0.001). Regression analysis identified several baseline variables as predictors of visual outcomes at 6 and 12 months, with different results depending on the analyzed group.
Both treatments were effective, although less effective than results reported in clinical trials. The morphologic response was better with ranibizumab compared to bevacizumab, although functionally there were no differences.
Eur J Ophthalmol 2017; 27(6): 756 - 761
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsSara Vaz-Pereira, Inês P. Marques, João Matias, Filipe Mira, Lígia Ribeiro, Rita Flores, on behalf of the Portuguese Multicenter Study Group of Retinal Vascular Diseases (PORTUGAL)*
- • Accepted on 29/01/2017
- • Available online on 28/02/2017
- • Published in print on 08/11/2017
This article is available as full text PDF.
- Vaz-Pereira, Sara [PubMed] [Google Scholar] 1, 2
- Marques, Inês P. [PubMed] [Google Scholar] 3
- Matias, João [PubMed] [Google Scholar] 4
- Mira, Filipe [PubMed] [Google Scholar] 5
- Ribeiro, Lígia [PubMed] [Google Scholar] 6
- Flores, Rita [PubMed] [Google Scholar] 7, 8, * Corresponding Author (firstname.lastname@example.org)
- on behalf of the Portuguese Multicenter Study Group of Retinal Vascular Diseases (PORTUGAL)*
Department of Ophthalmology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon - Portugal
Department of Ophthalmology, Faculty of Medicine, Universidade de Lisboa, Lisbon - Portugal
AIBILI Association for Innovation and Biomedical Research on Light and Image, Coimbra - Portugal
Department of Ophthalmology, Centro Hospitalar do Baixo Vouga, Aveiro - Portugal
Department of Ophthalmology, Centro Hospitalar Médio Tejo, EPE, Torres Novas - Portugal
Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia e Espinho, Vila Nova de Gaia - Portugal
Department of Ophthalmology, Centro Hospitalar de Lisboa Central, Lisbon - Portugal
Department of Ophthalmology, Nova Medical School, Lisbon - Portugal
* Members of the Portuguese Mutlicenter Study Group of Retinal Vascular Diseases (PORTUGAL) are listed in the Appendix